Showing 1189 results
- Media Release /Die Aktionäre bewilligen die 22. Dividendenerhöhung in Folge. Für 2018 wird die Dividende auf CHF 2.85 (+2%) je Aktie erhöht, was einer Rendite von 3,1% und einem Anteil von etwa 57% des freien…
- Media Release /Les actionnaires approuvent la 22e hausse consécutive du dividende à CHF 2.85 (+2%) par action pour 2018, soit un rendement de 3,1% et une distribution du free cash-flow d'environ 57% Une…
- Key Release /Basel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of…
- Media Release /Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea…
- Media Release /Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver…
- Key Release /Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz stieg um +4% (kWk1, –2% USD), wobei sich das operative Kernergebnis um +8% (kWk, 0% USD) verbesserte Innovative…
- Media Release /Sandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet familiar…
- Media Release /Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma…
- Key Release /Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising…
- Media Release /The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in…
Pagination
- ‹ Previous page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- …
- 119
- › Next page